Shots:
- Foresee has entered into an exclusive global licensing agreement with Primevera for its MMP-12 inhibitor programs, which incl. FP-025, FP-020 & third-generation MMP-12 inhibitors in discovery stage
- As per the deal, Foresee USA will receive a $10M upfront, ~$574.5M in milestones, & tiered single-digit royalties, or alternatively a tiered share of sublicense proceeds in lieu of milestones and royalties, plus a 19% equity stake in Primevera
- Primevera will fund all further development of its MMP-12 inhibitors; FP-020 is advancing toward an IND for a P-II trial for asthma, with FDA submission expected in early 2026, while FP-025 will enter P-II studies for rare diseases
Ref: PRnewswire | Image: Foresee & Primevera | Press Release
Related News: Foresee Pharmaceuticals Reports P-III (Casppian) Study Data of FP-001 in Children with CPP
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
